ID   MCF-7/5-23
AC   CVCL_4V44
SY   MCF 7/5-23; MCF 5-23; 5-23
DR   cancercelllines; CVCL_4V44
DR   Wikidata; Q54904349
RX   PubMed=8244585;
RX   PubMed=10070856;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen.
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 4172; GATA3; Simple; p.Asp336Glyfs*17 (c.1006dupG); Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 8975; PIK3CA; Simple; p.Glu545Lys (c.1633G>A); ClinVar=VCV000013655; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175.
DI   NCIt; C4194; Invasive breast carcinoma of no special type
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0031 ! MCF-7
SX   Female
AG   69Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 05-10-23; Version: 13
//
RX   PubMed=8244585; DOI=10.1002/ijc.2910550529;
RA   Hu X.F., Veroni M., de Luise M., Wakeling A.E., Sutherland G.R.,
RA   Watts C.K.W., Zalcberg J.R.;
RT   "Circumvention of tamoxifen resistance by the pure anti-estrogen ICI
RT   182,780.";
RL   Int. J. Cancer 55:873-876(1993).
//
RX   PubMed=10070856; DOI=10.1038/sj.bjc.6690112;
RA   Parisot J.P., Hu X.F., de Luise M., Zalcberg J.R.;
RT   "Altered expression of the IGF-1 receptor in a tamoxifen-resistant
RT   human breast cancer cell line.";
RL   Br. J. Cancer 79:693-700(1999).
//